Cohen's Point72 Pours $14M In This Biotech Stock That Gained 250% In A Month
Steve Cohen's Point72 Asset Management added Palisade Bio to the hedge fund's portfolio amid the company's announcement of positive phase 1 trial data and funding to advance phase 2 trials.
